Status:
COMPLETED
The Clinical Significance of Minimal Change in Reflux Esophagitis Based on the Gastroesophageal Reflux Disease Questionnaire
Lead Sponsor:
AstraZeneca
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
20+ years
Brief Summary
The purpose of this study is to define the endoscopic findings of minimal change that is significant to clinical significant reflux esophagitis. Through this, the investigators want to estimate the ap...
Eligibility Criteria
Inclusion
- Age ≥ 20 years old patients who consent to revealing their medical information and be able to respond to questionnaires regarding the symptom.
- Patients who had shown the reflux esophageal minimal change in the endoscopic finding: the reflux esophagitis
Exclusion
- Patients who had shown the mucosal break or barrett esophagus at gastric mucosal barrier or lower oesophagus in endoscopic findings
- Patient with a diagnosis of gastroesophageal reflux disease and who have received medication treatment
- Patient who had received H2-receptor antagonists, prostaglandin, PPI, NSAIDs or aspirin, high dose steroid and anticoagulants for at least 5 consecutive days in the 4-week period immediately preceding the diagnostic endoscopy
- Patients with a history of operation due to gastrointestinal disease, malignancy, alcoholism, pregnancy (in female), breast feeding (in female) or systemic disease
Key Trial Info
Start Date :
April 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
1550 Patients enrolled
Trial Details
Trial ID
NCT00901004
Start Date
April 1 2009
End Date
September 1 2009
Last Update
December 7 2010
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Busan, South Korea
2
Research Site
Daegu, South Korea
3
Research Site
Daejun, South Korea
4
Research Site
Kwangju, South Korea